"The flatness your antidepressant can't reach."

I want to tell you something that should be obvious but apparently isn’t — not to most women, not to most general practitioners, and not even to most psychiatrists.

You can be on an antidepressant that is working. Your depression is managed. You are not crying in your car. You are functioning. And you can still have a flat, motivationless quality that is real, that is specific, and that your antidepressant cannot touch — not because the medication is wrong, but because it is solving a different problem in a different system entirely.

This is not a story about my antidepressant failing me. It’s a story about how I spent years adjusting the wrong lever.

I was not depressed. Something was still wrong.

I have been on an antidepressant for 30 years. I’m not ashamed of this. It does what it’s supposed to do. I do not have clinical depression the way I had it before medication — the bottomless weight, the inability to see forward, the feeling that the ground had dropped out. That’s gone. Has been for decades.

What crept in through my 40s was something different. Quieter. Harder to name and easier to explain away.

Not sadness. Not inability to function. I was functioning fine. But something underneath the function was flat.

The project I’d been excited about now felt like it had a ceiling. The willingness to start things — to walk into a blank slate and feel the pull of possibility — went quiet. I used to wake up with ideas I wanted to chase. That became waking up with ideas I noted, organized, and then didn’t pursue with any particular urgency.

I thought I was becoming more realistic. I thought this was what wisdom looks like at 52. I thought the drive I’d had when I founded adoption.com in 1995 — when I was running orphanages in three countries simultaneously and still had energy left over to pick fights about internet strategy — was a feature of youth, not a feature of biology. I grieved it quietly and moved on.

What I didn’t know: that flatness has a name. And it had a cause. And it wasn’t coming from the system my antidepressant was working on.

Name it first: anhedonia.

The clinical term is anhedonia. It is technically defined as the loss of pleasure or motivation in activities that previously brought pleasure or motivation — but that definition undersells it, because it makes it sound like sadness. It isn’t sadness.

Anhedonia is the loss of the pull. The wanting. The dopamine-mediated signal your brain sends that says go toward that thing, that’s worth doing. Not the ability to enjoy something once you’re doing it — the motivation to initiate. To start. To care enough to begin.

It shows up not as “I am unhappy” but as “I don’t particularly feel like it.” As a low hum of indifference where enthusiasm used to be. As the absence of the hunger to pursue things. As a quieter, more manageable version of yourself that you mistake — easily, understandably — for maturity.

Women describe this to me in almost identical language:

“I’m just less driven than I used to be.” “I’ve become more of a settler.” “I don’t start things the way I once did. I guess I’ve outgrown that.”

None of them call it anhedonia. None of them connect it to hormones. They connect it to aging. And then they move on, because there doesn’t seem to be anything to do about aging.

There is something to do. But you have to understand why first.

The two systems. The two problems.

Here is the scientific core of what I wish someone had explained to me a decade ago.

SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors) — the most commonly prescribed antidepressants — work primarily on serotonin pathways. Serotonin regulates mood stability, emotional reactivity, anxiety. When clinical depression involves a dysregulated serotonin system, SSRIs are the right tool. They work for what they work for.

My own antidepressant is duloxetine — an SNRI that increases serotonin and norepinephrine. It’s a well-studied drug with a strong track record. What it does not do is meaningfully affect dopamine. That’s not a flaw; it wasn’t designed to. There is one commonly prescribed antidepressant that does act on the dopamine system: Wellbutrin (bupropion). I tried it. It gave me heart palpitations and I had to discontinue it. Which means I was left with the drug that handles the serotonin system — and nothing addressing the dopamine system at all. When I started testosterone, I wasn’t supplementing something I had other options for. I was filling a gap that, for cardiac reasons, I had no pharmaceutical path to fill any other way.

Testosterone-deficiency anhedonia runs through a completely different system: dopamine.

Specifically, testosterone upregulates the dopamine wanting signal in the brain through several mechanisms: it increases tyrosine hydroxylase, the enzyme that produces dopamine. It upregulates D2 and D5 dopamine receptor sensitivity. And it acts on androgen receptors in the ventral tegmental area — the origin point of the mesolimbic pathway, which is the brain’s core motivational and reward circuit. The VTA is where the limbic “wanting” signal and the prefrontal “doing” signal both originate. When testosterone is adequate, that system runs. When it drops, the signal weakens. The pull toward things dims.

These systems are neighbors, not the same building. An antidepressant that is working perfectly on the serotonin system will not touch the dopamine system. It isn’t supposed to. It wasn’t designed to.

This is not well understood in general medicine. Women on SSRIs who report persistent flatness, loss of motivation, or diminished drive are routinely told their medication needs adjusting. Sometimes they’re switched to a different antidepressant. Sometimes they’re offered a higher dose. Sometimes they’re told this is just how things are at this stage of life. Almost never are they told: your antidepressant is working correctly, and you have a separate problem in a different system that it cannot address.

A note on timing.

This picture doesn’t look the same at every stage. In early perimenopause — late 30s into mid-40s, still cycling but noticing changes — testosterone is fluctuating rather than uniformly declining. The flatness may come and go with your cycle rather than sitting as a constant background hum. By late perimenopause and into postmenopause, the decline becomes more consistent, and so does the signal-weakening in the dopamine pathway. If you’re earlier in the transition and the flatness is intermittent, that fits the picture. If you’re further along and it’s become a steady state, that fits too.

There’s a third group worth naming: women who had their ovaries removed — whether for endometriosis, cancer prevention, or another reason — often experience the sharpest and most sudden testosterone drop of all. Surgical menopause doesn’t taper; it stops. The motivational flatness can arrive within weeks of surgery, not months or years. If this is your situation, the timing signals in this article still apply — but your baseline was likely disrupted earlier and more abruptly than gradual menopause, which matters for how your provider interprets your labs.

The investigation is the same either way.

What the evidence shows.

The research on testosterone and anhedonia in women is not perfect. No one has ever run a randomized controlled trial with anhedonia as the primary endpoint — which is its own indictment of how seriously medicine has taken this question.

But the observational evidence is striking. A 2024 UK observational study of 510 women on testosterone therapy tracked symptom response across every category measured — and as observational data, it cannot rule out placebo response, the natural course of treatment, or healthy-user effects. With that caveat clearly on the table: of all the symptoms studied, anhedonia — “loss of interest in most things” — had the highest response rate: 56%. [Glynne et al., Archives of Women’s Mental Health, 2024] An uncontrolled study cannot prove causation. But 56% as the single most responsive symptom, in 510 women, in a peer-reviewed journal, is a signal that deserves the adequately powered trial it has never received.

Higher than libido, which is the symptom medicine usually mentions when it mentions testosterone at all. Higher than crying spells. Higher than every other symptom on the scale.

Fifty-six percent. The single most responsive symptom. In a dataset of over 500 women. And no randomized trial has ever made it a primary endpoint.

The RCTs that have “failed to show benefit” for testosterone on mood and motivation in women had serious design problems: immunoassay measurement error at female-range testosterone concentrations significant enough that the Endocrine Society called results below 150 ng/dL neither analytically nor clinically useful (meaning the dosing was essentially unmeasured), study durations of 8–12 weeks that conflated two very different timescales, and primary endpoints focused on sexual function rather than motivation.

Here’s the timescale distinction that the trials mostly missed: testosterone affects the dopamine system on two different horizons. The acute effect — increased dopamine release and receptor sensitivity — happens within 24–72 hours of a dose. That’s the “wanting” signal coming back online fast. The structural neuroplasticity changes — new receptor expression, axonal remodeling, changes to the VTA itself — take weeks to months to establish. When I describe feeling the difference within 48 hours of an injection, I’m describing the acute dopaminergic effect, not a placebo response. The studies that ran 12 weeks weren’t necessarily measuring at the right endpoint — they were looking for sexual function improvements in women who often weren’t deficient enough to show dramatic acute effects in a controlled lab setting, and they weren’t even looking at anhedonia. One 2020 trial found no significant difference from placebo at 8 weeks and didn’t control for SHBG — the binding protein that determines how much testosterone is actually available to brain tissue. The trials didn’t disprove the mechanism — but they also weren’t designed to test it. These trials measured different endpoints in different populations — sexual function outcomes in women who often weren’t deficient at concentrations the immunoassays couldn’t measure accurately anyway — and their null findings were then cited as evidence that testosterone has no effect on motivation. That’s not what a null finding shows. It shows that if you don’t measure what you’re looking for, you won’t find it.

The dopaminergic mechanism is well-supported in pre-clinical research — in receptor binding studies, in animal models, in the VTA distribution data — and the observational clinical evidence is consistent with it. What has not yet happened is an adequately powered RCT with anhedonia as a primary endpoint in menopausal women. That is not the same as the mechanism being disproven. It means the right trial hasn’t been run. The clinical evidence is building. The RCTs are behind — not because the hypothesis is implausible, but because there’s no FDA-approved product for women’s testosterone, which means there’s no commercial incentive to fund the trials that would exist if there were.

My experience, specifically.

Thirty years on an antidepressant. It does its job. That part isn’t the story.

What I can now see, looking back, is that the flatness that came in through my 40s was not my antidepressant failing. My antidepressant was handling the serotonin system. What it couldn’t handle — because it wasn’t designed to — was the dopamine signal weakening as my testosterone declined.

I thought I’d become more realistic. I thought I’d outgrown the drive to start things. I thought this was what wisdom looked like.

When testosterone was restored, the flatness lifted. My antidepressant hadn’t changed. I hadn’t changed anything else. The dopamine-mediated wanting came back — and I recognized it not as something new, but as the thing that had been missing. The pull toward the work. The excitement to pursue an idea all the way to the end instead of organizing it into a folder and moving on. The appetite to bet on myself.

I can feel the difference with a precision that I didn’t expect. I know when my injection is overdue because the flatness starts coming back at the edges. Not dramatically. But a warmth dims. A hum goes quieter. When I get the injection, it returns within 48 hours. I am not describing a placebo effect. I am describing a pharmacokinetic reality: testosterone enanthate has a half-life of approximately 4.5 days, which means by day 9 or 10 on a two-week schedule, I’m at a fraction of peak. The flatness at the edges has a cause and it has a schedule.

My antidepressant was never wrong. It was just solving a different problem. Knowing the difference isn’t a small thing. It’s the difference between adjusting a medication that’s working correctly for a decade and addressing the actual deficiency.

What to do if this sounds familiar.

If you’re on an antidepressant that is managing your depression and you still experience flatness, motivational deadness, loss of drive toward things you used to care about — this is worth investigating as a separate question. Not instead of your depression management. In addition to it.

Ask specifically about testosterone. Not just “hormones.” Testosterone. Ask for:

Total testosterone
Free testosterone by equilibrium dialysis — the gold-standard method. Not calculated free T, not an analog assay. The method matters: the Endocrine Society has formally stated that direct immunoassays at female-range testosterone concentrations are “neither analytically nor clinically useful,” and independent testing has found mean bias up to 200% compared to mass spectrometry. [Rosner et al., J Clin Endocrinol Metab, 2007; Vesper et al., Asian J Androl, 2014] When you ask for this test, give your doctor the specific order: LabCorp test 500726 (Testosterone, Free, Mass Spectrometry/Equilibrium Dialysis) or Quest test 36170 (Testosterone, Free (Dialysis) and Total, MS). Almost nobody in the patient-facing menopause space is telling you this test code exists — but it does, it’s covered at most major labs, and it gives you an accurate number instead of a guess.
SHBG — Sex Hormone-Binding Globulin, the protein that binds testosterone and makes it biologically unavailable. High SHBG, which is common in women on oral estrogen or certain medications, can tank your free testosterone even if your total looks normal on paper.

A note on the prescribing landscape: testosterone therapy for mood, motivation, and anhedonia in women is currently off-label in the US — there is no FDA-approved testosterone product for women in any indication. This is one reason the testing and prescribing conversation works better with a menopause specialist than a general practitioner. It also means your prescriber will be working outside a standard protocol — which is precisely why measurement precision (equilibrium dialysis rather than immunoassay) matters: when there are no established dosing guidelines, an accurate baseline number is the only thing both you and your prescriber have to navigate from.

Be specific with your prescriber about what you’re describing. The word “libido” will route you to a sexual function conversation. That’s not the conversation. Say: “I’m not talking about libido. I’m talking about anhedonia — loss of drive, loss of motivation to initiate things I used to care about. I want to explore whether testosterone deficiency is contributing to this.” Name the word. Make it specific. Give your doctor a problem they can investigate rather than a vague complaint they can dismiss as aging.

For Black women specifically, the dismissal problem runs deeper and in both directions. In psychiatry, anhedonia in Black patients is systematically undertreated — studies consistently show Black women are less likely to have their mood symptoms taken seriously and more likely to have them attributed to external circumstances rather than biology. In hormone medicine, testosterone is rarely offered to Black women, and the WHI’s “HRT causes cancer” headlines reinforced avoidance in a community that already had reason to distrust the medical system. The practical consequence: if you’re a Black woman and you bring this to your doctor, you may need to be more explicit, more persistent, and more prepared to ask for a second opinion. The Menopause Society provider finder is still the right starting point — but go in knowing that you may need to advocate harder, and that the dismissal, if it comes, is not evidence that the question is wrong.

For Latinas navigating this in a clinical environment where the menopause conversation is still 10–20 years behind, there are additional layers: cultural framing that treats emotional flatness as a natural consequence of a busy life rather than a clinical symptom, providers who have had no exposure to testosterone prescribing for women, and in some countries a laboratory infrastructure that may not have equilibrium dialysis available locally. The principle is the same. The advocacy often looks different.

If this resonates, the labs are the concrete next step. You’re not looking for a verdict. You’re looking for information that tells you whether there’s a gap worth addressing. If the labs show a deficiency, that’s a solvable problem. If they show adequate levels, that rules out this particular mechanism and points toward different questions. Message your doctor’s office through your patient portal today and request these three labs explicitly. Copy this language if it helps: “I’d like to test my hormone levels with a focus on testosterone — specifically total testosterone, free testosterone by equilibrium dialysis (not calculated, not analog assay), and SHBG.” If your doctor doesn’t know what equilibrium dialysis is, that’s useful information. It means your next step is finding a menopause specialist, not adjusting the medication that’s already working. The Menopause Society has a provider finder at menopause.org — filter for providers who list testosterone as a specialty. A psychiatrist knows the serotonin system. A menopause specialist knows the testosterone system. You need someone who can see both charts at once.

If access to a menopause specialist is a barrier — geographic, insurance, or financial — the lab request can still be initiated through your primary care physician. The test codes work at major commercial labs nationwide, and the results are the starting point for a specialist referral if your current provider isn’t comfortable proceeding.

But here’s what most women don’t know about lab costs.

The same equilibrium dialysis testosterone test that costs $200–$400+ when ordered through a standard doctor’s office visit — where the lab bills your insurance at inflated rates and your deductible kicks in — can cost $15–$30 if you order it yourself, directly, and pay cash. This isn’t a secret discount. It’s just how cash pricing works when you cut the insurance middleman out of a routine blood draw.

You don’t need a doctor’s order. Several direct-to-consumer lab services let you order the exact tests we’ve been discussing — total testosterone, free testosterone by equilibrium dialysis, SHBG — at a fraction of clinic pricing:

LabCorp OnDemand (ondemand.labcorp.com) — order directly from LabCorp, the same lab your doctor uses. You choose the tests, pay the cash price, go to any LabCorp draw site.
Quest MyQuest / QuestDirect (questdiagnostics.com/direct) — Quest’s equivalent. Same idea.
Ulta Lab Tests (ultalabtests.com) — discount aggregator that resells LabCorp and Quest capacity at 50–80% below retail. Good for panels.
Walk-In Lab (walkinlab.com) — another aggregator with competitive pricing on individual tests.
Marek Health (marekhealth.com) — specifically serves the functional and optimization medicine community. Physician oversight is often included in their pricing, and their testosterone panel options are calibrated for people who actually care about accurate measurement.

There’s also a question worth asking any functional medicine or menopause specialist you see: “What’s your cash price for labs?” Many practices have relationships with labs that give them dramatically reduced pricing — pricing they can pass directly to cash-pay patients, often far cheaper than what your insurance negotiates. The billing code your doctor uses and the price you pay are not as tightly connected as you might assume.

One more wrinkle worth knowing: even if you have insurance, running labs through insurance can cost you more, not less. If you haven’t hit your deductible, you’re paying close to the full billed rate anyway — which is the inflated list price, not the cash price. Running it outside insurance entirely, through one of the direct-pay services above, often ends up cheaper than the out-of-pocket share you’d owe after your insurance “discount.” It depends on your plan and where you are in the deductible year. But it’s worth checking the cash price before assuming insurance is the better path.

The point isn’t to avoid your doctor. The point is that getting an accurate baseline number doesn’t have to mean a $300 line item. The labs we’ve been talking about — the ones that tell you whether this gap is actually there — are accessible without a referral and without a large bill.

Two systems. Two tools. Neither one wrong.

The antidepressant is doing its job. It was always doing its job. The problem is that it was doing the serotonin job while the dopamine system was running on low testosterone, and nobody connected those two facts.

For women who’ve spent years adjusting doses, switching medications, wondering why they still feel flat when the depression is technically managed — this distinction is not an abstraction. It’s the difference between another 10 years on the wrong question and actually getting the right answer.

The flatness isn’t an inevitable feature of getting older. In a lot of cases, it’s a deficiency in a specific, testable, correctable system. And when you know which system, you can address it directly — without touching the thing that’s already working.

One more reason the labs matter beyond motivation: the same testosterone deficiency that quiets your drive also plays a role in muscle maintenance, bone density, and metabolic function — emerging evidence suggests these structural effects are real, even if the clinical picture for mood and motivation is further along. [Davis SR, et al. J Clin Endocrinol Metab. 2019;104(10):4660–4666. doi:10.1210/jc.2019-01603] The motivational symptoms are often the first thing women notice — but they’re not the only system running low. Getting tested addresses more than one problem at once.

Go get the labs. Ask the right question. And if your antidepressant is working, don’t let anyone tell you it isn’t, just because something else is also wrong.

Sources

Glynne S, Kamal A, Kamel AM, Reisel D, Newson L. Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study. Archives of Women’s Mental Health. 2024 Sep 16;28(3):541–550. doi:10.1007/s00737-024-01513-6 — UK observational cohort, n=510; loss of interest in most things had the highest response rate of all symptoms at 56%.
Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Utility, Limitations, and Pitfalls in Measuring Testosterone: An Endocrine Society Position Statement. J Clin Endocrinol Metab. 2007 Feb;92(2):405–413. doi:10.1210/jc.2006-1864. PMID: 17090633 — Endocrine Society position: direct immunoassays below 150 ng/dL are neither analytically nor clinically useful; equilibrium dialysis is the reference standard.
Vesper HW, Botelho JC, Wang Y. Challenges and improvements in testosterone and estradiol testing. Asian J Androl. 2014;16(2):178–184. doi:10.4103/1008-682X.122338. PMID: 24407184 — Documents mean bias of 5%–220% for immunoassays vs. mass spectrometry at female-range testosterone concentrations.

Sources

Keep reading

Get the research, not the reassurance.